Role of Chemotherapy in Hodgkin’s Lymphoma
Authors:
- 1 March 2009
- journal article
- research article
- Published by Wolters Kluwer Health in The Cancer Journal
- Vol. 15 (2) , 150-154
Abstract
The development of curative chemotherapy regimens for the treatment of Hodgkin’s lymphoma (HL) is one of the true success stories in oncology. Most patients diagnosed with HL today can be cured. The major task remaining before us is curing as many patients as possible with their initial therapeutic approach while minimizing the acute toxicities and limiting the lifetime risks of important secondary events such as cardiovascular complications and secondary malignancies. In the 40 years since DeVita et al. developed the mechlorethamine, vincristine, procarbazine, and prednisone chemotherapy regimen, we have learned a great deal about risk stratification to minimize treatment-related toxicity. Positron emission tomography may further assist us in reducing radiation treatment without compromising cures. This review will discuss the development of the chemotherapy regimens used in the management of early and advanced stage HL and the advantages and disadvantages of their use in combination with radiation therapy.Keywords
This publication has 43 references indexed in Scilit:
- Chemotherapy plus Involved-Field Radiation in Early-Stage Hodgkin's DiseaseNew England Journal of Medicine, 2007
- Early Interim 2-[18F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Is Prognostically Superior to International Prognostic Score in Advanced-Stage Hodgkin's Lymphoma: A Report From a Joint Italian-Danish StudyJournal of Clinical Oncology, 2007
- Two Cycles of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine Plus Extended-Field Radiotherapy Is Superior to Radiotherapy Alone in Early Favorable Hodgkin's Lymphoma: Final Results of the GHSG HD7 TrialJournal of Clinical Oncology, 2007
- ABVD Versus Modified Stanford V Versus MOPPEBVCAD With Optional and Limited Radiotherapy in Intermediate- and Advanced-Stage Hodgkin's Lymphoma: Final Results of a Multicenter Randomized Trial by the Intergruppo Italiano LinfomiJournal of Clinical Oncology, 2005
- Consolidation Radiation After Complete Remission in Hodgkin's Disease Following Six Cycles of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine Chemotherapy: Is There a Need?Journal of Clinical Oncology, 2004
- Randomized Comparison of ABVD and MOPP/ABV Hybrid for the Treatment of Advanced Hodgkin’s Disease: Report of an Intergroup TrialJournal of Clinical Oncology, 2003
- A Prognostic Score for Advanced Hodgkin's DiseaseNew England Journal of Medicine, 1998
- Decreasing Risk of Leukemia with Prolonged Follow-up after Chemotherapy and Radiotherapy for Hodgkin's DiseaseNew England Journal of Medicine, 1987
- Gonadal toxicity after combination chemotherapy for Hodgkin's disease. Comparative results of MOPP vs ABVDEuropean Journal of Cancer and Clinical Oncology, 1985
- Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPPCancer, 1975